In this week’s news, concerns about medtech manufacturing costs, Lonza teams with 3D printing firm, China oks 1st CDMO made mAb and more.
Medtech firms need to streamline manufacturing networks
Drug device manufacturers could save money if they streamlined their fragmented networks according to McKinsey & Co.
The conclusion come from a new report, which revealed production and logistics costs in the device sector are higher than they need to be.
According to the authors while some manufacturers have cut production costs 10 to 15% and reduced lead time by 20 to 30% by partnering with CDMOs and logistics firms, many have not.
“Most medtech companies still struggle with their manufacturing and distribution networks, for a variety of reasons” the authors wrote, citing firms whose networks have grown unwieldy through acquisitions as an example.
They conclude that “Network optimisation is rapidly becoming a necessity if medtech companies want to stay competitive in today’s markets.”
Lonza teams with 3D printing specialist to make organs for drug discovery
Swiss CDMO Lonza has partnered with Allevi to serve customers looking to make organs and tissues for drug discovery.
According to a Bioprocess Insider report the deal will see Lonza combine its primary cells and culture media portfolio with Philadelphia-based Allevi’s range of bioprinter and bioink production tech.
3D printing – also known as additive manufacturing – involves depositing materials sequentially to form a structure. A bioink is a made from living cells that can be formed into a scaffolding that supports the organ.
China oks first CDMO-made mAb under DAL
China has approved the first CDMO-made mAb under drug regulations adopted last year.
Regulators approved tislelizumab, a drug for Hodgkin’s lymphoma developed by BeiGene and made in China by Boehringer Ingelheim.
China’s Drug Administration Law (DAL) was revised in August. The changes introduced a marketing authorisation holder (MAH) system and formalised rules on contract manufacturing.
Drug firms set for year of new safety questions for old meds
Pharmaceutical firms are likely to face renewed safety questions about older products this year according to an expert quizzed by Fiercepharma.
David Light, founder and CEO of Valisure, told the publication that US FDA efforts to detecte the carcinogen N-nitrosodimethylamine (NDMA) – so far identified in valsartan, ranitidine and DFM – will be extended to other medicines this year.
Also in the news
Contract pharma took a look at a busy year of drug approval at the US FDA. See full story here.
The Motley Fool shared a list of the top 10 performing healthcare stocks of 2019. Top of the list is eye disease drug developer Kodiak Sciences, whose share price increased 800%.
Interesting reading ahead the JP Morgan Healthcare Conference this month.
PMLive ran a feature examining the importance of mission statements in pharmaceutical R&D. Having a scientific ambition and aim in mind is key according to author Brian Smith from Bocconi and the University of Hertfordshire.
Developments of note in the contract manufacturing sector.
iBio has asked EdgePoint to implement an AI system at its cGMP manufacturing facility in Texas. According to iBio the system will automatically document, timestamp, verify, and track data and activities in its pharmaceutical manufacturing operations. See press release.
Great Point Partners has invested $6.6m in cell and gene therapy CDMO Orgenesis. The payment is part of a wider stock purchase announced last year. See press release for details.